Maria Rosselson, MD
Ophthalmology · Highland Park, ILNPI 1871615419
Payments from drug & device makers
Across 217 payments — averaging $86.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$11K
- Alcon$2K
- Rxsight Inc$1K
- Ocular Therapeutix, Inc.$829
- AbbVie$731
- Glaukos Corporation$578
- plus $3K from 27 others
What the payments were for
- Consulting fees$2,10026%
- Speaking & faculty fees$3514%
- Food & beverage$5,41367%
- Education$1021%
- Gifts$1091%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch Health US, LLC | 2 | $10,750 |
| Alcon | 27 | $1,708 |
| Rxsight Inc | 8 | $1,224 |
| Ocular Therapeutix, Inc. | 15 | $829 |
| AbbVie(2 entities) | 43 | $731 |
| Glaukos Corporation | 7 | $578 |
| Mallinckrodt Hospital Products Inc. | 13 | $392 |
| Notal Vision, Inc. | 1 | $319 |
| Sight Sciences, Inc. | 7 | $280 |
| Novartis | 13 | $246 |
| NEW World Medical,inc. | 10 | $205 |
| Sun Pharmaceutical Industries Inc. | 6 | $202 |
| Harrow Eye, LLC | 7 | $184 |
| Amgen(2 entities) | 9 | $182 |
| Eyevance Pharmaceuticals LLC | 8 | $131 |
| Kala Pharmaceuticals, Inc. | 7 | $128 |
| Bausch & Lomb Americas Inc. | 5 | $110 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $95 |
| Oyster Point Pharma, Inc. | 3 | $60 |
| Tarsus Pharmaceuticals, Inc. | 3 | $56 |
| Beaver-visitec International, Inc. | 2 | $49 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $47 |
| Thea Pharma Inc. | 2 | $44 |
| Dompe US, Inc. | 2 | $42 |
| Biotissue Holdings Inc. | 2 | $41 |
| Akorn Operating Company LLC | 2 | $38 |
| Aerie Pharmaceuticals, Inc. | 2 | $37 |
| Ivantis, Inc | 1 | $27 |
| Shire North American Group Inc | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| Lensar, Inc. | 1 | $17 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXTENZA$1,800
- RXSIGHT CONTACT LENS$1,138
- RXSIGHT INJECTOR CARTRIDGE$1,138
- RXSIGHT INJECTOR HANDPIECE$1,138
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$1,138
- LIGHT ADJUSTABLE LENS (LAL)$1,030
- iDoseTR$414
- iStent Infinite$203
- AcrySof IQ PanOptix UV IOL$132
- OMNI(R) SURGICAL SYSTEM (US)$125
- AcrySof$116
- CEQUA$114
- Clareon$110
- AcrySof IQ VIVITY IOL$109
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$109
- Centurion$108
- VUITY$102
How this compares
$18,826 in reported general payments places this provider in the 85th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 44 | $49,098 |
| LumiganBimatoprost | 65 | $31,166 |
| Cyclosporine | 58 | $25,205 |
| XiidraLifitegrast | 20 | $20,637 |
| VyzultaLatanoprostene Bunod | 17 | $8,117 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 33 | $8,101 |
| Brimonidine Tartrate | 96 | $4,449 |
| Prednisolone Acetate | 114 | $3,850 |
| Travoprost | 17 | $3,436 |
| ZioptanTafluprost/Pf | 12 | $3,156 |
| Alphagan PBrimonidine Tartrate | 15 | $2,845 |
| Timolol Maleate | 164 | $2,026 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 110 | $1,755 |
| Latanoprost | 213 | $1,734 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 11 | $1,677 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $731 | $83,109124 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $110 | $28,75437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Highland Park
- Parag MajmudarHighland Park$559K
- Neel VaidyaHighland Park$226K
- Veeral ShethOak Forest$14.8M
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.9M
- Manjot GillChicago$1.4M
- Mitchell JacksonLake Villa$1.4M
- Ramanath BhandariSpringfield$1.2M
- Kathleen MornoNorth Riverside$1.2M
- Amani FawziChicago$864K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.